OXiGENE to Present at Merriman Curhan Ford and Lazard Healthcare Conferences Nov 10, 2009
Source: OXiGENE, Inc. ... Nov. 10, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: - ) (Stockholm: - ), a clinical stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that OXiGENE Management will present a corporate overview and update at the Merriman Curhan Ford Investor Summit at 12:00 noon EST (9:00 a.m. PST) today at the Sofitel Hotel in New York City, N.Y. ... OXiGENE is a clinical-stage biopharmaceutical company developing novel... (Primezone Releases)
OXiGENE to Acquire VaxGen in a Stock-for-Stock Merger Oct 15, 2009
Source: OXiGENE, Inc. ... Acquisition to Add Approximately $33 Million in Cash to OXiGENE's Balance Sheet Conference Call Today at 9:00 AM Eastern ... Oct. 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: - ) (Stockholm: - ), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, and VaxGen, Inc. (OTCBB: - ), a biopharmaceutical company, announced today that they have entered into a definitive merger agreement pursuant to which OXiGENE will... (Primezone Releases)
NexTalk Appoints Jeff Webber and Bill Shiebler to Board of Directors, Names Shiebler Chairman Aug 1, 2009
He has served on the board of directors of OxiGene and Attensity Corp. Mr. Shiebler served at the request of President George W. Bush on the Presidential Commission on Medicaid, and was a Trustee of the Salt Lake Olympic Committee. "As we embark on our new growth strategy, we could not ask for more talented and experienced leadership and governance on for its Board of Directors," said CEO Todd Wakefield. (PR Newswire)
OXiGENE Reports Second Quarter 2009 Financial Results; Company Continues to Achieve Pipeline Progress With Strengthened Cash Position Jul 30, 2009
Source: OXiGENE, Inc. ... July 30, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: - ; Stockholm: - ), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended June 30, 2009 and presented an update on recent clinical and corporate progress ... The Company reported that the net loss attributable to OXiGENE for the second quarter of 2009 was $5. (Primezone Releases)
OXiGENE Announces Closing of Registered Direct Offering Jul 21, 2009
Source: OXiGENE, Inc. ... July 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: - ; Stockholm: - ), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, today announced that it has closed a registered direct offering of 6,250,000 units of its common stock and warrants as described below, at a price of $1 ... OXiGENE's gross proceeds from the offering were approximately $10 million. (Primezone Releases)
OXiGENE Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology Jul 6, 2009
Source: OXiGENE, Inc. ... July 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq: - ; Stockholm: - ), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the Company exercised its option to acquire all of the equity of Symphony ViDA, Inc. in exchange for six million newly-issued shares of OXiGENE common stock, subject to adjustment as described below ... 08 per share, the closing market price of OXiGENE common stock on July 2,... (Primezone Releases)
OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology Jun 25, 2009
" Clinicians and other medical professionals who would like more information about this study may contact OXiGENE at 650-635-7000. About PCV The choroid is the vascular layer at the back of the eye that lies between the retina and the sclera. In patients with PCV, dense clusters of polyp-like vascular structures, or polypoids, can be observed on the choroid with ICG angiography. Studies suggest that these polypoids may exist in up to one-third of wet AMD patients. The vascular phenotype of these... (Primezone Releases)
OXiGENE Appoints Dr. Peter J. Langecker as Chief Development Officer Jun 17, 2009
Press Release Source: OXiGENE, Inc. ... June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the appointment of Peter J. Langecker, M.D., Ph ... Dr. Langecker will oversee the development of OXiGENE's drug candidates, ZYBRESTAT(tm) for oncology, ZYBRESTAT for ophthalmology, and OXi4503. (Primezone Releases)
Stock Alerts to Watch on May 26th by PennyStockChaser: NFLD, SAY, ARUN, OXGN, ULU and RF May 26, 2009
Stock alerts include: Northfield Laboratories (NASDAQ:), Satyam Computer Service Ltd. (NYSE:), Aruba Networks Inc. (NASDAQ:), OXiGENE Inc. (NASDAQ:), Ulu Inc. (AMEX:) and Regions Financial Corp. (NYSE:). About PennyStockChaser. (PR Newswire)
OXiGENE Announces Clinical Data to be Presented At the 2009 Annual Meeting of the American Society of Clinical Oncology May 21, 2009
Press Release Source: OXiGENE, Inc. ... May 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that results from a Phase 2 clinical trial of its vascular disrupting agent (VDA) product candidate, ZYBRESTAT (fosbretabulin), in women with platinum-resistant ovarian cancer, will be presented in a symposium at the upcoming 2009 Annual Meeting of the American... (Primezone Releases)
OXiGENE Announces First Quarter 2009 Earnings Conference Call and Webcast May 4, 2009
Press Release Source: OXiGENE, Inc. ... May 4, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report first quarter 2009 results on Monday, May 11, 2009 ... A conference call and webcast hosted by OXiGENE management will begin at 4:30 p.m. EDT (1:30 p.m. PDT). (Primezone Releases)
OXiGENE Begins Phase 1b/2a Trial of OXi4503, a Novel Second-Generation Vascular Disrupting Agent Apr 6, 2009
Press Release Source: OXiGENE, Inc. ... April 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that the company has initiated a Phase 1b/2a study of its dual-mechanism, second-generation vascular disrupting agent (VDA), OXi4503, in patients with solid tumors with hepatic involvement ... I am pleased to be working with OXiGENE in the clinical evaluation of OXi4503, which... (Primezone Releases)
Oxigene narrows loss on cost cuts, gain Mar 23, 2009
Oxigene (Nasdaq: OXGN) booked a $1 ... Oxigene s cash on hand at the end of 2008 totaled $18 ... In February, Oxigene said it secured $40 million in financing to help fund drug development programs and daily operations. (Boston Business Journal, MA)
OXiGENE Reports Fourth Quarter and Year-End 2008 Results Mar 20, 2009
Source: OXiGENE, Inc. ... March 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and year ended December 31, 2008 ... In the fourth quarter of 2008, OXiGENE recorded a non-cash gain totaling $3. (Primezone Releases)
OXiGENE Announces Publication of Phase 2 Study Results With Fosbretabulin (ZYBRESTAT(tm)) Monotherapy in Anaplastic Thyroid Cancer (ATC) Mar 17, 2009
Source: OXiGENE, Inc. ... March 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the publication of results from a 26-patient, Phase 2 study of fosbretabulin (ZYBRESTAT) in anaplastic thyroid cancer (ATC) in the current issue of the journal THYROID. The authors of the study, titled ``A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma... (Primezone Releases)
OXiGENE Announces Fourth Quarter and Fiscal 2008 Earnings Conference Call and Webcast Feb 19, 2009
Source: OXiGENE, Inc. ... Feb. 19, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (NasdaqGM: - ) (Stockholm: - ), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report fourth quarter and fiscal year-end 2008 results, along with guidance for 2009, on Thursday, February 26, 2009 ... A conference call and webcast hosted by OXiGENE management will begin at 4:30 pm EST (1:30 p.m. PST). (Primezone Releases)
